EMAIL THIS PAGE TO A FRIEND

The Yale journal of biology and medicine

Guanfacine for the treatment of cognitive disorders: a century of discoveries at Yale.


PMID 22461743

Abstract

The prefrontal cortex (PFC) is among the most evolved brain regions, contributing to our highest order cognitive abilities. It regulates behavior, thought, and emotion using working memory. Many cognitive disorders involve impairments of the PFC. A century of discoveries at Yale Medical School has revealed the neurobiology of PFC cognitive functions, as well as the molecular needs of these circuits. This work has led to the identification of therapeutic targets to treat cognitive disorders. Recent research has found that the noradrenergic α2A agonist guanfacine can improve PFC function by strengthening PFC network connections via inhibition of cAMP-potassium channel signaling in postsynaptic spines. Guanfacine is now being used to treat a variety of PFC cognitive disorders, including Tourette's Syndrome and Attention Deficit Hyperactivity Disorder (ADHD). This article reviews the history of Yale discoveries on the neurobiology of PFC working memory function and the identification of guanfacine for treating cognitive disorders.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

G1043
Guanfacine hydrochloride, ≥98% (HPLC)
C9H9Cl2N3O · HCl